What Venn Life Sciences does

Venn Life Sciences is a contract research organization (CRO) that delivers clinical trial services spanning pre-clinical through Phase III, with a particular concentration in early-phase and human challenge trial work. The company has been consolidated, alongside hVIVO, Cryostore, and CRS, under the unified 'One hVIVO' brand, operating as a wholly-owned subsidiary of the AIM-listed hVIVO group. Venn Life Sciences brings historical drug development consulting, clinical operations, and biostatistics capability to the platform, complemented by the group's purpose-built UK and German clinical research facilities, CL3 laboratories, HTA-licensed cryostorage and biobanking, and world-leading human challenge trial models covering RSV, Influenza, COVID-19, HRV, hMPV, Malaria, and Asthma & COPD. The combined entity positions itself as an integrated early-phase drug development platform with capabilities across consultancy, clinical delivery, laboratory services, recruitment, and storage.

Revenue is generated primarily through project-based, professional services contracts negotiated per study scope, phase, therapeutic area, and complexity, with multi-year contract cadences. The customer base is segmented vertically across global pharma, biotech, CROs, start-ups, and drug development investors, served through a direct enterprise field sales motion with no resellers or distributors. The go-to-market leverages thought leadership via scientific publications, webinars, industry conferences (BIO International, World Vaccine Congress Europe, BIO-Europe), and small expert-led workshops targeted at technical due diligence and target product profile discussions.

Venn Life Sciences itself has a track record of inorganic growth, completing five acquisitions between 2010 and 2015 (DCI France, CRM Clinical Trials, medevol, Cardinal Systems SAS, Kinesis Pharma B.V.) before being integrated into the One hVIVO platform. The group continues to invest in capacity, including a new Canary Wharf headquarters facility opened in June 2024, the January 2025 acquisition of German CRO CRS, and the first-in-Europe deployment of Bio-Rad's Droplet Digital PCR technology. The firm operates with 51-100 employees and trades on the London Stock Exchange.

Name

Venn Life Sciences

Legal name

hVIVO Services Limited

Website

https://vennlifesciences.com

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

51–100 employees

Short description

Venn Life Sciences is a CRO delivering pre-clinical through Phase III clinical trial services, now operating as a subsidiary within the AIM-listed One hVIVO group, which specializes in human challenge trials, integrated clinical operations, bioanalysis, and cryobiobanking for global pharma, biotech, and investors.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Data Management, Biostatistics & Statistical Programming FSP (HLAGAOAB), Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Clinical trial services
• Drug development consulting
• Contract research organization
• Human challenge trials
• Bioanalytical laboratory services

Headquarters

HQ city

Dalkey

HQ country

Ireland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Clinical Trial Services: Full-service CRO offering end-to-end clinical trial delivery across Phase I-III. Revenue generated through project-based contracts for clinical trial management, with services including medical monitoring, data management, project management, and quality assurance.
2. Drug Development Consulting: Strategic and scientific consultancy services including regulatory affairs, CMC consulting, due diligence, and medical writing. Provides investor readiness consulting for biotech clients.
3. Laboratory Services: Comprehensive laboratory services including bioanalysis, virology, immunology, biomarker analysis, and PBMC processing. Integrated with clinical operations for consistent data generation.
4. Human Challenge Trials: Specialist challenge trial services generating early efficacy data for vaccines and therapeutics. Includes virus production, characterization, and clinical delivery.
5. Biobank and Storage Solutions: Cryostorage and biobanking services for biological samples and clinical materials with HTA licensing.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Venn Life Sciences provides contract clinical research services from pre-clinical through Phase III, delivering full-service CRO capabilities including clinical trial management, regulatory affairs, biostatistics, medical monitoring, and data management. The company also offers drug development consulting (CMC, regulatory, non-clinical, due diligence, PK/PD), specialized human challenge trials for infectious disease, bioanalytical and virology laboratory services, and HTA-licensed cryostorage and biobanking. Services are delivered to pharmaceutical, biotechnology, and CRO customers across the UK and Germany under the integrated One hVIVO brand.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Solutions Comprehensive Phase I–III clinical trial delivery including medical monitoring, data management, project management, biostatistics, quality assurance, medical writing, regulatory affairs, clinical trial sites, recruitment, and clinical PK/PD services for pharma and biotech sponsors.
• Drug Development Consulting Strategic and scientific consultancy covering regulatory affairs, CMC consulting, non-clinical development, due diligence, biosample project management, statistics and study design, clinical PK/PD and translational modelling, medical writing, and clinical trials legal services for drug development sponsors and investors.
• Human Challenge Trials Specialist controlled-pathogen challenge trials in dedicated quarantine facilities using proprietary models for RSV, Influenza, COVID-19, HRV, hMPV, Malaria, and Asthma & COPD, including virus production and characterization, participant screening and recruitment, and clinical delivery to generate early efficacy data.
• Laboratory Solutions Advanced laboratory services across bioanalysis and characterization, virology, immunology, molecular biology, microbiology, PBMC processing, assay development and validation, preclinical PK/PD studies, and Bio-Rad Droplet Digital PCR for clinical trial sponsors.
• Biobank and Storage Solutions HTA-licensed cryostorage and biobanking services with multi-temperature storage, 24/7 monitoring, full chain-of-custody management, and fast local access for biotech, pharma, and research partners' biological samples and clinical materials.
• Integrated Solutions End-to-end integrated drug development platform combining clinical, laboratory, recruitment, and consultancy expertise, including the Speed to Clinic Accelerator, Investor Readiness Consulting, Integrated Clinical Trial Delivery, Translational Research Consulting, and EU Expansion Strategy for sponsors.

Quantifiable outcome

• 1,900+ trials completed successfully
• +2 more outcomes

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• CRS (Clinical Research Services)coreStrategic or Co-development Partner · 1 January 2025German clinical research company acquired by hVIVO in January 2025. CRS operates clinical research facilities in Germany and is now integrated under the unified One hVIVO brand, extending capabilities in early-phase clinical trials and recruitment.
• CryostorecoreStrategic or Co-development PartnerSpecialist cryostorage and biobanking company acquired by hVIVO. Provides HTA-licensed cryostorage and biobanking services with multi-temperature storage, 24/7 monitoring, and full chain-of-custody management. Now part of the integrated One hVIVO brand.
• Bio-Rad LaboratoriescoreTechnology or IntegrationhVIVO became the first in Europe to deploy Bio-Rads Droplet Digital PCR technology, enhancing bioanalysis and characterization capabilities for clinical trials and laboratory services.
• Venn Life SciencescoreStrategic or Co-development PartnerAcquired company now operating under the unified One hVIVO brand. Part of the strategic integration bringing together hVIVO, Cryostore, CRS, and Venn Life Sciences to offer fully integrated early-phase drug development solutions.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Pharmaron: Integrated CRO/CDMO offering lab services, preclinical research, clinical trial support and drug development consulting. Comparable to hVIVO's integrated early-phase platform with comparable sponsor base and similar emphasis on accelerating biotech drug development.
• Medpace: Mid-sized global CRO focused on Phase I-IV clinical development with strong medical, regulatory and biostatistics expertise. Closely comparable operating model to hVIVO in serving small-to-mid biotech with full-service early-phase trials, though without the specialized human challenge franchise.
• Worldwide Clinical Trials: Mid-sized global CRO with Phase I-IV capabilities across complex therapeutic areas. Comparable in size and sponsor mix to hVIVO, particularly for biotech and specialty pharma early-phase work.

Broad incumbents

• ICON plc: One of the world's largest clinical CROs offering Phase I-IV trial delivery, lab services and consulting. Significantly larger and more diversified than hVIVO, but directly competes for the same global pharma and biotech sponsors seeking integrated early-phase and Phase II/III delivery.
• IQVIA: Global mega-CRO with clinical operations, real-world data, laboratory and consulting services. Comparable to hVIVO in serving pharma/biotech sponsors with integrated drug development solutions, but at vastly greater scale and geographic reach.
• Charles River Laboratories: Preclinical and clinical CRO with strong biologics and laboratory services franchises. Comparable to hVIVO in combining preclinical/early-phase research capabilities with safety and bioanalytical lab services for pharma and biotech sponsors.
• Parexel International: Global full-service CRO with Phase I-IV capabilities, biostatistics, regulatory affairs and bioanalytical services. Competes with hVIVO for pharma and biotech early-phase contracts but with materially greater global infrastructure.
• Syneos Health: Global biopharma solutions organization combining clinical CRO services with commercial capabilities. Competes with hVIVO for full-service Phase I-III trials and consultancy work from pharma and biotech sponsors.
• SGS Health & Nutrition: Diversified testing, inspection and certification company with a life sciences/CRO division including early-phase clinical and bioanalytical services. Comparable to hVIVO's lab and clinical research capabilities, particularly in infectious disease and vaccine studies, though SGS operates across many non-pharma verticals.
• Eurofins Scientific: Global laboratory services group with a significant clinical trial laboratory and central lab business. Comparable to hVIVO in providing bioanalytical, virology, immunology and biomarker lab services to pharma and biotech sponsors, though without equivalent clinical operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/vennlifescience
• Facebookfacebook.com/vennlifesciences
• LinkedInlinkedin.com/company/venn-life-sciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Venn Life Sciences